TD Private Client Wealth LLC Increases Position in United Therapeutics Corporation (NASDAQ:UTHR)

TD Private Client Wealth LLC lifted its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 29.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,762 shares of the biotechnology company's stock after buying an additional 1,092 shares during the period. TD Private Client Wealth LLC's holdings in United Therapeutics were worth $1,468,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Jones Financial Companies Lllp lifted its stake in United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after purchasing an additional 258 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its stake in United Therapeutics by 29.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 675 shares of the biotechnology company's stock worth $238,000 after purchasing an additional 155 shares during the last quarter. Atria Investments Inc lifted its stake in United Therapeutics by 6.6% during the fourth quarter. Atria Investments Inc now owns 905 shares of the biotechnology company's stock worth $319,000 after purchasing an additional 56 shares during the last quarter. M&T Bank Corp lifted its stake in United Therapeutics by 9.4% during the fourth quarter. M&T Bank Corp now owns 3,429 shares of the biotechnology company's stock worth $1,210,000 after purchasing an additional 294 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new stake in United Therapeutics during the fourth quarter worth $22,658,000. 94.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

UTHR has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research note on Monday, May 5th. Morgan Stanley increased their price target on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research note on Thursday, May 1st. Cantor Fitzgerald initiated coverage on United Therapeutics in a research note on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price target for the company. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Finally, Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $384.62.

United Therapeutics Stock Up 2.1%

United Therapeutics stock traded up $6.14 during trading hours on Wednesday, reaching $300.56. 416,382 shares of the company's stock were exchanged, compared to its average volume of 446,729. The firm's 50 day simple moving average is $300.95 and its 200 day simple moving average is $321.35. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82. The firm has a market capitalization of $13.56 billion, a PE ratio of 11.99, a PEG ratio of 6.36 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The business's revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.17 EPS. Analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Richard Giltner sold 3,036 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the transaction, the director owned 19,384 shares in the company, valued at approximately $5,613,606.40. The trade was a 13.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Nilda Mesa sold 645 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the transaction, the director owned 4,883 shares of the company's stock, valued at $1,416,021.17. This trade represents a 11.67% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 76,681 shares of company stock worth $22,813,739. 10.30% of the stock is currently owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.